With $30M and Stanford immunotherapy pioneer, biotech eyes one of the toughest brain diseases
July 09, 2020 at 11:03 AM EDT
The startup believes it not only has a drug that could fix the process behind ALS and frontotemporal dementia but also a biomarker that could speed development.
